Cipla announced its partnership with, Eli Lilly and Company (India), a 100% subsidiary of Eli Lilly and Company, a global multinational pharmaceutical leader, for the marketing and distribution of Lilly's
BASAGLAR (insulin glargine injection) in India. Under this agreement, Lilly's BASAGLAR that is manufactured by Lilly will be marketed and distributed in India by Cipla.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
